189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial

作者：Nadja Harbeck, Oleg Gluz, Mathias Christgen, Ulrike Anneliese Nitz, Manuela Braun, M.A.M. Thill, Rachel Würstlein, T. Link, Andreas Daniel Hartkopf, Christian Schem, Vesna Bjelic‐Radisic, Mathias R. Warm, M.K. Graeser-Mayer, Katja Krauss, Oliver Hoffmann, Kerstin Lüedtke-Heckenkamp, Christine zu Eulenburg, Peter Schmid, HH Kreipe, Sherko Küemmel · 发表于：ESMO Open · 年份：2025 · DOI：10.1016/j.esmoop.2025.104743 · 被引用次数：12 · 研究领域：Advanced Breast Cancer Therapies、Breast Cancer Treatment Studies、Lung Cancer Research Studies

WSG ADAPTcycle (NCT 04055493) investigates whether pts with intermediate-risk early breast cancer (EBC) and no endocrine response (ET-resp.) or with intermediate/high-risk EBC and ET-resp. identified by clinical factors, OncotypeDx (RS) and Ki67 ≤10% after preoperative ET, derive survival benefit from ribociclib (Ribo) + ET vs chemotherapy (CT) +ET. (Neo)adjuv. therapy was allowed. We present the first results from ADAPTcycle, addressing optimal treatment in HR+/HER2- EBC with uncertain CT benefit.